Ian George Barron, Ghassan Abdallah, Unni Heltne
Moderation analyses support the robustness of RCT findings: ScouT's superior efficacy in reducing parent-rated peer-related aggression seems to hold across various characteristics. However, children with high levels of internalizing symptoms and high DBD symptom severity may need more targeted or longer treatment. The small effect sizes of the moderation effects limit the relevance of the findings for clinical practice. Age, functional impairment, and internalizing symptoms predict outcome irrespective of the treatment modality. These findings should inform future hypothesis-testing studies.
The study evaluated the efficacy of the Children and Grief Manual for Palestinian adolescents who experienced multiple overlapping losses and prolonged grief because of COVID-19, the genocide in Gaza, and the increased military, and settler violence in the West Bank. One hundred and nineteen adolescents referred to school counselors in the occupied West Bank for prolonged grief received 7 two-hour sessions of the Manual on a weekly basis. A pre-post and 9-month follow-up design utilized measures of prolonged grief disorder (PGD), posttraumatic stress disorder (PTSD), and depression and assessed program fidelity and a measure of future cost. Interviews were conducted with counselors and adolescents. The study found high levels of program fidelity (8.6/10) leading to significantly reduced PGD (d = 0.449), PTSD (d = 0.729), and depression (d = 0.400) at post-test. Gains were maintained for PTSD (d = 0.407) and PDG (d = 0.137) at follow-up. Counselors reported that the Manual was a healing experience that was highly tolerated by adolescents. For scaling up, the Manual was relatively inexpensive to deliver. In settings of ongoing violence, it is recommended that repetition of the Manual or booster sessions be considered to support the maintenance of gains. A significant limitation of the study was the pre-post-test follow-up design. Future research needs to include pragmatic randomized control trials.